Summary
75 / 100 · Bulios Score
What speaks for it
- It earns 21 NOK a year on every 100 NOK of invested capital.
- It holds more cash than debt: 162.4M kr against 9.40M kr.
- The share price is below the Bulios Fair Price.
- Out of every 100 NOK of revenue, 12 NOK is left as net profit.
What to watch
- It missed profit estimates 4 times in the last 8 quarters.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.2 NOK for 1 NOK of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (NOK)
Diluted EPS (NOK)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 11% a year.
Growth in detailDoes it make money?
Very wellWhere 100 NOK of revenue goes
- Cost of sales 8.6 NOK
- Sales and administration 60 NOK
- Taxes and other 20 NOK
- Net profit 12 NOK
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 14 NOK
Out of every 100 NOK of revenue, 12 NOK is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.